

## 4DMEDICAL SUCCESSFULLY COMPLETES A\$40M PLACEMENT TO SUPPORT DEVELOPMENT & COMMERCIALISATION OF XVD SCANNERS<sup>™</sup>

---

- 4DMedical receives commitments for A\$40.0 million via a Placement at A\$1.55 per share
  - The Placement received significant support from new and existing institutional and sophisticated investors from both Australia and overseas
  - Proceeds from the Placement will primarily fund, in conjunction with the \$28.9m of MRFF funding, the development and commercialisation of the world's first dedicated lung function scanner – XVD Scanner<sup>™</sup>. It was a commitment of the grant bid to the MRFF that 4DMedical provide new capital for the development of the XVD Scanner
  - The Placement proceeds will also provide balance sheet flexibility to pursue identified growth opportunities
  - XVD Scanners will be integrated with 4DMedical's proprietary XV Technology<sup>™</sup>, significantly increasing the addressable revenue opportunity and driving the adoption of the Company's core Software-as-a-Service (SaaS) offering which remains 4DMedical's primary focus
  - The Company anticipates that Generation One XVD Scanners will be placed in hospitals for clinical trials in early 2022
  - The Company will also offer a Share Purchase Plan (SPP) of up to A\$3.0 million at A\$1.55 to provide eligible shareholders the opportunity to participate in the capital raise – details will be released to shareholders shortly
  - Andreas Fouras, 4DMedical's CEO, [will host a webinar](#) to discuss the grant, capital raising and the Company's SaaS offering at 9:30am AEDT today, Thursday 4 March 2021.
- 

**4 March 2021:** 4DMedical Limited (ASX:4DX, "4DMedical" or the "Company"), a medical technology company focused on commercialising its patented respiratory imaging platform, is pleased to announce it has completed a share placement (Placement) to institutional and sophisticated investors. The Placement will raise approximately A\$40.0 million before costs.

The Placement will result in the issue of approximately 25.8 million shares at A\$1.55 per share (Placement Shares), within the Company's existing 15% placement capacity under ASX Listing Rule 7.1. The issue price represents a 10.4% discount to last closing price on 25 February 2021.

The Placement and SPP follow the Company's announcement released to ASX on 2 March 2021 that the Australian Lung Health Initiative Pty Ltd (ALHI), a consortium incorporated and led by 4DMedical, was granted A\$28.9 million in funding from the Australian Federal Government's Medical Research Future Fund (MRFF) Frontier Health and Medical Research initiative. The funding will be provided in tranches over the next five years.

The grant funding will be used by ALHI to develop two generations of XVD Scanner™, the world's first dedicated lung function scanner. The XVD Scanner will integrate with 4DMedical's XV LVAS software, to provide safe and rapid lung analysis for both adults and children.

Proceeds raised under the Placement and SPP will be primarily used to accelerate development and commercialisation of the XVD Scanner. It was a commitment of the grant bid to the MRFF that 4DMedical provide new capital for the development of the XVD Scanner. Funds raised will also provide balance sheet flexibility to pursue identified growth opportunities that have the potential to drive commercialisation of XV LVAS.

**4DMedical Founder and CEO Andreas Fouras** said:

"While our focus remains on the execution of our XV LVAS commercialisation strategy, we now have the opportunity to develop and commercialise the XVD Scanner, which will complement our software-as-a-service (SaaS) offering by significantly increasing the addressable revenue opportunity.

"4DMedical will have full commercialisation rights for XVD Scanners and lead sales and marketing for these products. The Company expects to start commercialising the Generation One XVD Scanner in 2023, two years before the Generation Two version which is expected to be commercialised in 2025. ALHI has already delivered a Generation One concept scanner using the funding from the MRFF Stage One grant awarded in April 2019.

"This Placement and SPP will provide us with the funds needed to execute the long-term commercialisation strategy for XVD Scanners, which will open up an additional revenue stream for the business and drive the adoption of XV LVAS at medical institutions.

"The capital raising also provides us with balance sheet flexibility for future growth opportunities that can accelerate the commercialisation of XV LVAS product, which remains the focus of the Company."

Placement Shares are expected to settle on 10 March 2021.

Bell Potter Securities Limited and E&P Corporate Advisory were Joint Lead Managers and bookrunners to the Placement.

### **Share Purchase Plan offer to Eligible Shareholders**

4DMedical will offer existing eligible shareholders the opportunity to participate in a Share Purchase Plan (SPP) to raise up to an additional A\$3 million. Under the SPP, eligible shareholders will be able to apply for up to A\$30,000 of new shares at the same price as the Placement.

The Company may decide to accept applications (in whole or part) that result in the SPP raising more or less than this amount, in its absolute discretion.

Further information regarding the SPP, including the SPP terms and conditions, will be outlined in a separate SPP Booklet which is expected to be despatched to eligible shareholders and released on the ASX on Monday 15 March 2021.

The indicative timetable for the SPP offer is set out below, however the Company reserves the right to vary the dates and times without notice.

### **Indicative Placement and SPP Timetable**

The timetable below is indicative only and subject to change. The Company reserves the right to alter the below dates at its full discretion and without prior notice, subject to the ASX Listing Rules and the Corporations Act. The commencement of trading of new shares is subject to confirmation from the ASX.

Date	Event
7:00pm (AEDT*) Wednesday 3 March 2021	Record Date for Eligible Shareholders to subscribe for new shares via the SPP
Thursday 4 March 2021	Announcement of the Placement and SPP
Wednesday 10 March 2021	Settlement of Placement Shares
Monday 15 March 2021	Expected date of issue of the Placement Shares and commence trading on the ASX
Monday 15 March 2021	Dispatch of SPP booklet and SPP opening date
5:00pm (AEDT*) Monday 29 March 2021	Closing Date for SPP
Wednesday 31 March 2021	Announcement of results of the SPP
Wednesday 7 April 2021	Issue of new shares under the SPP

\* Australian Eastern Daylight Time

## Capital Raising Presentation

Further details of the MRFF program and capital raising are included in the presentation lodged with the ASX on Thursday 4 March 2021.

## Management Webinar

The Company's Founder and CEO, Andreas Fouras, will host a webinar to discuss the MRFF grant, capital raising and discuss 4DMedical's SaaS offering at 9:30am AEDT today, Thursday 4 March 2021.

To register to attend the webinar, please click the link below:

[https://us02web.zoom.us/webinar/register/WN\\_N060ADVESY-GUUFZUD7i2g](https://us02web.zoom.us/webinar/register/WN_N060ADVESY-GUUFZUD7i2g)

## ENDS

Authorised by the 4DMedical Board of Directors.

### Contacts:

#### Corporate

Charlene Stahr  
Company Secretary  
companysecretary@4dmedical.com

#### Investor

Simon Hinsley  
+ 61 401 809 653  
shinsley@4dmedical.com

#### Media

Matthew Wright  
+ 61 451 896 420  
matt@nwrcommunications.com.au

### About 4DMedical:

Based in Melbourne, Australia and Los Angeles, USA, 4DMedical (formerly 4Dx) was founded in 2012 and is listed on the Australian Securities Exchange (ASX: 4DX).

4DMedical is a medical technology company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders including: coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer.

The unique 4DMedical technology accurately and quickly scans lung function as the patient breathes, to assist in providing sensitive, early diagnosis, and to monitor changes over time. Our Software-as-a-Service (SaaS) scans deliver much more complete results, showing even subtle variations in lung function down to the finest details, using lower levels of radiation than traditional methods.

Respiratory diagnosis is a US\$31 billion per annum global industry. Through its technology 4DMedical provides clinicians with greater insights into diseases of the lung. 4DMedical is focused on providing better information to doctors and patients about lung function. Better information means better decisions, and better outcomes.